Wall Street analyst estimates for Innate Pharma S.A. (IPHA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.67 |
Valuation Ratios
| Price / Book | -6.93 |
| EV / EBITDA | -2.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.2M | $32.6M | $79.9M | $69.0M | $69.8M | $12.1M | $57.7M | $51.9M | $12.6M | $2.8M |
| Cost of Revenue | $48.6M | $67.0M | $69.6M | $45.2M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | 0 |
| Gross Profit | $7.5M | -$34.4M | $10.3M | $23.8M | $20.1M | -$22.3M | $6.0M | $5.6M | $12.6M | $2.8M |
| Research & Development | $48.6M | $67.0M | $69.6M | $1.6M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $43.6M |
| Selling, General & Admin | $9.3M | $16.2M | $19.3M | $49.6M | $19.0M | $25.5M | $14.5M | $11.7M | $11.9M | $11.0M |
| Operating Expenses | $48.6M | $72.6M | $74.7M | $50.9M | $19.0M | $25.5M | $63.4M | $18.3M | $64.2M | $56.2M |
| Operating Income | $7.6M | -$40.0M | $5.1M | -$27.1M | $1.1M | -$47.8M | -$57.4M | -$12.7M | -$51.6M | -$53.4M |
| EBITDA | $10.8M | -$35.6M | -$3.3M | -$20.9M | $13.3M | -$43.2M | -$12.3M | -$1.8M | -$46.9M | -$43.6M |
| Interest Expense | $124000 | $113000 | $102000 | $229445 | $341000 | $312000 | $288000 | $640000 | $566000 | $440000 |
| Pre-tax Income | $12.9M | -$48.0M | $2.7M | -$20.8M | -$829000 | -$45.5M | -$58.0M | -$7.6M | -$49.5M | -$49.2M |
| Income Tax | $301000 | $368000 | -$333000 | $206000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $12.6M | -$48.4M | $3.0M | -$20.8M | -$64.0M | -$52.8M | -$58.1M | -$7.6M | -$49.5M | -$49.2M |
| EPS | $0.23 | $-0.89 | $0.05 | $-0.31 | $-0.01 | $-0.57 | $-0.73 | $-0.09 | $-0.61 | $-0.53 |
| EPS (Diluted) | $0.23 | $-0.89 | $0.05 | $-0.31 | $-0.01 | $-0.57 | $-0.73 | $-0.09 | $-0.61 | $-0.53 |
| Shares Outstanding (Diluted) | $53.9M | $54.4M | $58.8M | $66.9M | $78.9M | $79.5M | $79.6M | $84.1M | $81.1M | $89.4M |
Price
| Price | $2.01 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | FR |
Related companies: APLT · CGEN · CRBP · CRDF · CYBN · ELTX · MIST
Explore sector: Healthcare · Biotechnology
More sections of IPHA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks